Sexually Transmitted Diseases Archives

Neisseria gonorrhoeae gonorrhoea gonorrhea

News and Trends 27 Jun 2023

GSK gonorrhea vaccine fast tracked

The US Food and Drug Administration (FDA) has granted a Fast Track designation for GSK plc’s Neisseria gonorrhoeae investigational vaccine (NgG). The vaccine candidate is currently in an ongoing phase II trial and aims to demonstrate proof of concept by assessing the efficacy of the NgG vaccine in healthy adults, 18 to 50 years of […]

June 27, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

Intravacc to develop intranasal gonorrhea vaccine with $14.6M NIH/NIAID contract

Intravacc has been awarded a contract with base and options that may total US$14.6 million for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). The contract has been awarded by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Gonorrhea is a sexually […]

October 5, 2022 - 3 minutesmins - By Jim Cornall

Startup Scout 7 Jul 2017

A Norwegian Biotech is Aiming at Permanently Removing HPV Skin Infections

This week we’re traveling to Bergen, a beautiful coastal city in Norway surrounded by seven mountains, where a biotech called Cytovation is developing a brand new treatment for benign tumors caused by the human papillomavirus. Mission: Cytovation is developing what could be the first prescription treatment for cutaneous warts, which are a form of […]

July 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Jun 2017

Results are in for Europe’s First Biobanking Study on HPV Cervical Cancer

The RAIDs consortium made its closing event last week. After 4.5 years of studies, it has managed to change our appreciation of HPV cervical cancer towards building intelligent targeted therapy designs. Every year in Europe, 16,000 women die from cervical cancer and another 34,000 are newly diagnosed, which makes it the second most frequent form […]

June 14, 2017 - 5 minutesmins - By Timothé Cynober

News and Trends 18 Oct 2016

€4M Grant for a Cancer Vaccine that could Bench its Competitors

Hookipa just secured a huge grant from the Austrian government. The plan is to develop the strongest HPV vaccine ever and claim its place in the €2B head and neck cancer market. Hookipa, one of the hottest Biotechs in Vienna, develops vaccines based on a new class of viral vectors. Its platform has impressed the public sector and secured €4.16M from the Austrian […]

October 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 12 at 12.23.30 PM e1476267908354

News and Trends 12 Oct 2016

Transgene teams up with big Players against HPV Head and Neck Cancer

Transgene is partnering with Merck and Pfizer to develop a combined therapy for head and neck cancer squamous cell carcinoma (HNSCC) caused by human papiloma virus (HPV) infections. A successful outcome will let the team access a €2B market niche. Transgene has been struggling for a while: last year it had to fire 40% of its workforce […]

October 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Jun 2016

After its drop earlier this year, Genticel goes back up the slope

Genticel has announced that not one but two milestones have been achieved in the development of its products, which focus on immunotherapies for cancers caused by the human papillomavirus. Genticel is developing GTL001 (named ProCervix in Europe) to answer an unmet medical need – the eradication of the virus HPV 16 or 18 (high-risk types that […]

June 17, 2016 - 3 minutesmins - By Jerome Topsent

News and Trends 10 Jun 2016

Genticel is vaccinating against Cervical Cancer AFTER Infection

Estonia, our previous destination by the Baltic Sea, was a delightful and a full of potential place to visit. This week, we are heading down to the relaxing and sunny south of France, more precisely to Toulouse, once the capital of the Visigothic Kingdom and current to the Midi-Pyrénées region, the largest region in metropolitan France. It […]

June 10, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 28 Jan 2016

Viral Immunotherapy Trial Failure Causes French Biotech Stocks to Drop 43%

Genticel (France) is a clinical biotech developing a cervical cancer immunotherapy against the Human papillomavirus. However, their 24-month phase II trial has failed to meet primary endpoint at its halfway point, and their stocks dropped 43% overnight. Around 70% of cervical cancer cases are caused by 2 types of Human papillomavirus (HPV): 16 and 18. And among the 300 million women around the […]

January 28, 2016 - 3 minutesmins - By Dani Bancroft

hypoxia cancer hpv inthera aglaia oncology

News and Trends 17 Dec 2015

The Assault on Solid Tumors: How ‘Blinding’ Cancer is an Attractive Therapeutic Approach

The Dutch Oncology VC Specialist Aglaia has invested €3.4M in the Swiss Start-Up Inthera Bioscience for their Small molecule platform against solid tumors. Aglaia is a venture capital firm based in Bilthoven (NL) which has 3 funds under their management for specialist investment into Oncology research. Last year they raised over €50M as part of […]

December 17, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 2 Jun 2015

Genticel aims to prevent Cancer caused by the Human Papillomavirus

Genticel is a step closer to prevent cancer caused by the human papillomavirus (HPV). The French biotech announced positive results of GTL002’s preclinical in vivo proof of concept, Genticel’s multivalent HPV therapeutic vaccine candidate based on the company’s versatile Vaxiclase platform. Vaxiclase is a technology platform that can be used with many antigens in several […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us